Terumo Neuro Unveils New SOFIA™ 88 Catheter Data Demonstrating Strong Performance Compared to Other Super-Bore Catheters
Terumo Neuro (OTC:TRUMY) has revealed new real-world physician preference data for its SOFIA™ 88 Neurovascular Support Catheter at the 2025 SNIS Annual Meeting. The data, collected from 105 procedures across 37 U.S. centers and 41 physicians, demonstrates strong performance compared to other super-bore catheters.
Key findings show that 95% of physicians reported reliable target location reach, and 86% rated SOFIA™ 88 as "Better" or "Much Better" than alternatives. The catheter outperformed competitors significantly, beating ZOOM 88 in 94% of cases and HiPoint 88 in 79% of cases.
The SOFIA™ 88 catheter, launched in the U.S. on May 13, 2025, is part of Terumo Neuro's integrated stroke solution portfolio, which includes the ERIC™ Retrieval Device, BOBBY™ Balloon Guide Catheter, and other specialized medical devices.
Terumo Neuro (OTC:TRUMY) ha presentato nuovi dati real-world sulle preferenze dei medici riguardo al suo catetere di supporto neurovascolare SOFIA™ 88 durante il meeting annuale SNIS 2025. I dati, raccolti da 105 procedure in 37 centri statunitensi e 41 medici, mostrano una performance superiore rispetto ad altri cateteri super-bore.
I risultati chiave evidenziano che il 95% dei medici ha riportato un'affidabile capacità di raggiungere la zona target, e l’86% ha valutato SOFIA™ 88 come "Migliore" o "Molto migliore" rispetto alle alternative. Il catetere ha superato significativamente i concorrenti, battendo ZOOM 88 nel 94% dei casi e HiPoint 88 nel 79% dei casi.
Il catetere SOFIA™ 88, lanciato negli Stati Uniti il 13 maggio 2025, fa parte del portafoglio integrato di soluzioni per l’ictus di Terumo Neuro, che include il dispositivo di recupero ERIC™, il catetere guida a palloncino BOBBY™ e altri dispositivi medici specializzati.
Terumo Neuro (OTC:TRUMY) ha dado a conocer nuevos datos de preferencia médica en condiciones reales para su catéter de soporte neurovascular SOFIA™ 88 en la Reunión Anual SNIS 2025. Los datos, recolectados de 105 procedimientos en 37 centros de EE.UU. y 41 médicos, muestran un rendimiento destacado en comparación con otros catéteres super-bore.
Los hallazgos clave indican que el 95% de los médicos reportaron un alcance confiable al objetivo, y el 86% calificó SOFIA™ 88 como "Mejor" o "Mucho mejor" que las alternativas. El catéter superó significativamente a sus competidores, ganando frente a ZOOM 88 en el 94% de los casos y a HiPoint 88 en el 79% de los casos.
El catéter SOFIA™ 88, lanzado en EE.UU. el 13 de mayo de 2025, forma parte del portafolio integrado de soluciones para el ictus de Terumo Neuro, que incluye el dispositivo de recuperación ERIC™, el catéter guía con balón BOBBY™ y otros dispositivos médicos especializados.
Terumo Neuro (OTC:TRUMY)는 2025년 SNIS 연례회의에서 SOFIA™ 88 신경혈관 지원 카테터에 대한 실제 의료진 선호도 데이터를 공개했습니다. 이 데이터는 미국 내 37개 센터와 41명의 의사들이 참여한 105건의 시술에서 수집되었으며, 다른 슈퍼보어 카테터에 비해 우수한 성능을 입증했습니다.
주요 결과로는 95%의 의사들이 목표 부위 도달이 신뢰할 만하다고 보고했으며, 86%는 SOFIA™ 88을 다른 제품보다 "더 나음" 또는 "훨씬 더 나음"으로 평가했습니다. 이 카테터는 경쟁 제품보다 현저히 뛰어나 ZOOM 88보다 94%의 경우에서 우위를 보였고, HiPoint 88보다 79%의 경우에서 우수했습니다.
2025년 5월 13일 미국에서 출시된 SOFIA™ 88 카테터는 ERIC™ 회수 장치, BOBBY™ 풍선 가이드 카테터 등과 함께 Terumo Neuro의 통합 뇌졸중 솔루션 포트폴리오의 일부입니다.
Terumo Neuro (OTC:TRUMY) a présenté de nouvelles données sur les préférences des médecins en conditions réelles concernant son cathéter de soutien neurovasculaire SOFIA™ 88 lors de la réunion annuelle SNIS 2025. Ces données, collectées lors de 105 procédures dans 37 centres américains et auprès de 41 médecins, démontrent une performance solide comparée à d'autres cathéters super-bore.
Les résultats clés montrent que 95 % des médecins ont signalé une atteinte fiable de la cible, et que 86 % ont évalué SOFIA™ 88 comme « Meilleur » ou « Bien meilleur » que les alternatives. Le cathéter a surpassé significativement ses concurrents, battant ZOOM 88 dans 94 % des cas et HiPoint 88 dans 79 % des cas.
Le cathéter SOFIA™ 88, lancé aux États-Unis le 13 mai 2025, fait partie du portefeuille intégré de solutions pour l’AVC de Terumo Neuro, qui comprend également le dispositif de récupération ERIC™, le cathéter guide à ballonnet BOBBY™ et d’autres dispositifs médicaux spécialisés.
Terumo Neuro (OTC:TRUMY) hat auf der SNIS-Jahrestagung 2025 neue Daten zur Präferenz von Ärzten im realen Einsatz für seinen SOFIA™ 88 Neurovaskulären Unterstützungskatheter vorgestellt. Die Daten, erhoben aus 105 Eingriffen in 37 US-Zentren bei 41 Ärzten, zeigen eine starke Leistung im Vergleich zu anderen Super-Bore-Kathetern.
Wesentliche Ergebnisse zeigen, dass 95 % der Ärzte eine zuverlässige Erreichung des Zielorts berichteten und 86 % bewerteten SOFIA™ 88 als „Besser“ oder „Viel besser“ als Alternativen. Der Katheter übertraf die Konkurrenz deutlich, indem er ZOOM 88 in 94 % der Fälle und HiPoint 88 in 79 % der Fälle schlug.
Der SOFIA™ 88 Katheter, der am 13. Mai 2025 in den USA eingeführt wurde, ist Teil des integrierten Schlaganfall-Lösungsportfolios von Terumo Neuro, zu dem auch das ERIC™ Retrieval Device, der BOBBY™ Ballonführungskatheter und weitere spezialisierte medizinische Geräte gehören.
- 95% physician success rate in reaching target locations, even in challenging anatomies
- 86% of physicians rated SOFIA™ 88 as Better or Much Better than alternatives
- Outperformed competitors with 94% success vs ZOOM 88 and 79% vs HiPoint 88
- Successfully launched and integrated into comprehensive stroke solution portfolio
- None.
Real-World
Collected from 105 procedures across 37 U.S. centers and 41 physicians, the preference test revealed:
95% of physicians reported that SOFIA™ 88 catheter reliably reached the target location—even in anatomically challenging cases, with59% of procedures in ICA-T or beyond86% of physicians rated the SOFIA™ 88 catheter as "Better" or "Much Better" than alternatives overall- Physician data included: SOFIA™ 88 catheter outperformed the ZOOM 88 catheter in
94% of cases and the HiPoint 88 catheter in79%
"These real-world results further validate SOFIA™ 88 catheter's position as a leading super-bore support catheter," said Carsten Schroeder, President and CEO of Terumo Neuro. "This new dataset reinforces what we've heard consistently from physicians: the SOFIA™ 88 catheter delivers reliable performance where it matters most. We are proud to see the catheter outperform other large-bore devices in real-world settings—and even more proud that this innovation was shaped through close physician partnership. It reflects our long-standing commitment to delivering meaningful neurovascular advancements rooted in evidence, experience, and collaboration."
The SOFIA™ 88 Neurovascular Support Catheter was commercially launched in the
The physician preference data unveiled at SNIS builds on results from the SOFAST registry, which demonstrated the safety and efficacy of the SOFIA™ Flow Plus 6F catheter as a frontline aspiration device.
The SOFIA™ 88 catheter is compatible with the SOFIA™ Flow Plus 6F Aspiration Catheter and is part of Terumo Neuro's fully integrated stroke solution, including:
- ERIC™ Retrieval Device – For thrombus control and procedural versatility
- BOBBY™ Balloon Guide Catheter – Offering reliable flow arrest with next-gen balloon technology
- WEDGE™ and HEADWAY™ Microcatheters – Designed for navigation support and access efficiency
- TRAXCESS™ Guidewires – Soft-tip wires built for challenging anatomies
About Terumo Neuro
We are in business to create and deliver Game-changing Impact™—innovations that redefine what is possible in neurovascular treatment to meaningfully advance both physician practice and patient outcomes. Founded in 1997 as MicroVention and acquired by Terumo Corporation in 2006, Terumo Neuro offers more than thirty products for the treatment of cerebral aneurysms, ischemic stroke, carotid artery disease, and neurovascular malformations. Headquartered in
About Terumo Corporation
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for 100 years. Based in
Reference
- Data on file
Media Contact:
Christine McCullough
Global Corporate Communications
Terumo Neuro
+1 714 206 9800
christine.mccullough@terumoneuro.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/terumo-neuro-unveils-new-sofia-88-catheter-data-demonstrating-strong-performance-compared-to-other-super-bore-catheters-302503950.html
SOURCE Terumo Neuro
FAQ
What are the key performance metrics of Terumo's SOFIA™ 88 catheter according to the 2025 physician preference data?
When was the SOFIA™ 88 Neurovascular Support Catheter launched in the US market?
How many procedures and physicians were involved in Terumo's SOFIA™ 88 catheter study?
What other products are included in Terumo Neuro's stroke solution portfolio?
How did SOFIA™ 88 perform in anatomically challenging cases?
